Abstract
Objective
Depo-Provera® is a contraceptive approved by the US Food and Drug Administration (FDA) since 1992 and used worldwide by more than 90 million women.
Aim of study
Despite the fact that progestins are endogenous hormones that are secreted by the body, its excess might lead to detrimental health effects. Whether progestins as contraceptives are friends or foes is a questionable matter. In this manuscript, we drive the attention to both usage and side effects Depo-Provera.
Results
Depot-medroxyprogesterone acetate (DMPA) is a highly effective, convenient non-daily hormonal contraceptive option that has been available worldwide for many years. The experience with DMPA provides a large body of long-term data regarding the efficacy and safety of this contraceptive method; this long-term experience has established that the use of DMPA does not increase the risk of cardiovascular events, breast cancer, other gynecologic malignancy, or postmenopausal fracture; however, patients are often more concerned about the relatively immediate effects of contraceptives such as potential changes in menstrual cycle, body weight, and mood disturbances.
Conclusion
Concerns about such issues may lead to reluctance to initiate therapy or premature discontinuation. Counseling and understanding of women’s concerns and experiences using Depo-Provera is important and could help health care providers redesign counseling strategies to improve contraceptive continuation and improve patient adherence.
Similar content being viewed by others
References
Camaggi CM, Strocchi E, Giovannini M (1983) Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administrations in advanced cancer patients. Cancer Chemother Pharmacol 11:19–22
Wright CE, Antal EJ, Gillespie WR (1983) Effect of injection volume on the bioavailability of sterile Medroxyprogesterone acetate suspension. Clin Pharm 2:435–438
Blossey HC, Bartsch HH, Kanne D (1982) The pharmacokinetics of high-dose Medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol 8:77–81
Speroff L, Glass RH, Kase NG (1989) Clinical gynecologic endocrinology and infertility. 4th ed. Williams & Wilkins, Baltimore, MD
Goodman-Gilman A, Rall TW, Nies AS (1990) Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. Pergamon, New York, NY, pp 1397–1401
Hatcher RA, Stewart F, Trussell J (1990) Contraceptive technology 1990–1992. 15th ed. Irvington, New York, NY
Speroff L, Darney PD (1992) A clinical guide for contraception. Williams & Wilkins, Baltimore, MD
Product Information (1998) Depo-Provera(R), medroxyprogesterone. The Upjohn Company, Kalamazoo, MI
Product Information (1999) Premphase (R), conjugated estrogens/medroxyprogesterone acetate. Wyeth Ayerst Laboratories, Philadelphia, PA
Di Celser K, Gruber C, Hayes C (1982) Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 2:229–232
Notelovitz M, Kitchens G, Ware M (1983) Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 62:596–600
Roche J (1984) Steroid-induced arachnoiditis. Med J Aust 140:281–284
Kirkham C, Hahn PM, Van Vugt DA (1991) A randomized, double-blind, placebo-controlled, cross-over trial to asses the side effect of medroxyprogesterone acetate in hormone replacement therapy. Obstet Gynecol 78:93–97
Guiloff E, Ibarra-Polo A, Zanartu J (1974) Effect of contraception on lactation. Am J Obstet Gynecol 118:42–45
Halderman LD, Nelson AL (2002) Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol 186:1250–1256
Amatayakul K, Sivasomboon B, Thanangkul O (1980) A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22:605–622
Moore LL, Valuck R, McDougall C, Fink W (1995) A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52:215–219
Bahamondes L, Diaz J, Petta C, Hall P (1998) Weight variation in users of the once-a-month injectable contraceptive cyclofem. Adv Contracept 14:223–230
Kaunitz AM (1999) Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 170:1543–1549
Risser WL, Gefter LR, Barratt MS, Risser JM (1999) Weight change in adolescents who used hormonal contraception. Adolesc Health 24:433–436
Espey E, Steinhart J, Ogburn T, Qualls C (2000) Depo-Provera associated with weight gain in Navajo women. Contraception 62:55–58
Bahamondes L, Del-Castillo S, Tabares G, Arce XE, Perrotti M, Petta C (2001) Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception 64:223–225
Mangan SA, Larsen PG, Hudson S (2002) Overweight teens at increased risk for weight gain while using depot medroxyprogesteroneacetate. J Pediatr Adolesc Gynecol 15:79–82
Shadoan MK, Anthony MS, Rankin SE, Clarkson TB, Wagner JD (2003) Effects of tibolone and conjugated equine estrogens with or without medroxyprogesterone acetate on body composition and fasting carbohydrate measures in surgically postmenopausal monkeys. Metabolism 52:1085–1089
Mia AR, Siddiqui NI, Khan MR, Shampa SS, Rukunuzzaman, Akhter M, Kamrunnaher (2004) Effect of prolonged use of injectable hormonal contraceptives on blood pressure and body weight. Mymensingh Med J 13:30–32
Goldsmith NF, Johnston JO (1975) Bone mineral: effects of oral contraceptives, pregnancy, and lactation. J Bone Joint Surg Am 57:657–668
Cundy T, Cornish J, Roberts H, Elder H, Reid IR (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92:569–573
Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR (1998) The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49:615–618
Scholes D, LaCroix AZ, Ott SM, Ichikawa LE, Barlow WE (1999) Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 93:233–238
Tong OS, Tang G, Yip PS, Li B (2000) Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception 62:161–164
Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK (1996) Stroke in users of low-dose oral contraceptives. N Engl J Med 335:8–15
Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A (2001) Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103:899–906
Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM (2002) Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13:581–587
Busen NH, Britt RB, Rianon N (2003) Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health 32:257–259
Lara-Torre E, Edwards CP, Perlman S, Hertweck SP (2004) Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17:17–21
Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192:1316–1323
Kaunitz AM (1996) Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 41:419–427
Valente PT, Schantz HD, Trabal JF (1998) Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate. Cancer 25:328–334
Jordan A (1994) Toxicology of depot medroxyprogesterone acetate. Contraception 49:189–201
Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T et al (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25:2798–2803
Brent RL (2005) Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 73:906–918
Eel-Gindi E, Ahmed-Nasr M (1993) Hormonal versus genetic factors in limb and heart anomalies. Cardiovasc Surg 1:381–383
Wilkins L (1960) Masculinization of female fetus due to use of orally given progestins. JAMA 172:1028–1032
Gal I (1967) Hormonal pregnancy tests and congenital malformation. Nature 216:83
Aarskog D )1970) Clinical and cytogenetic studies in hypospadias. Acta Paediatr Scand (suppl 203):1–62
Heinonen OP (1977) Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med 296:67–70
Roberts IF, West RJ (1977) Teratogenesis and maternal progesterone. Lancet II:982
Evans ANW (1980) The ingestion by pregnant women of substances toxic to the foetus. Practitioner 224:315–319
Mann JR (1983) Transplacental carcinogenesis (adrenocortical carcinoma) associated with hydroxyprogesterone hexanoate. Lancet II:580
Ambani LM, Joshi NJ, Vaidya RA, Devi PK (1977) Are hormonal contraceptives teratogenic? Fertil Steril 28:791–797
Bracken MB, Holford TR, White C, Kelsey JL (1978) Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 7:309–317
Saksena SK, Salmonsen R, Lau IF (1979) Termination of pregnancy in the rat by RMI 12,936. Contraception 19:481–488
Lau IF, Hoogasian J, Wong SK, Saksena SK (1980) Effects of prostaglandin F2 alpha and an antiprogestational steroid, RMI 12,936, on rat pregnancy. Prostaglandins Med 4:121–132
Nora JJ, Nora AH, Blu J, Ingram J, Fountain A, Peterson M, Lortscher RH, Kimberling WJ (1980) Exogenous progestogen and estrogen implicated in birth defects. IARC Sci Publ, pp 169–178
Savolainen E, Saksela E, Saxen L (1981) Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1:521–524
Starkov MV, Shashkina LF, Remezova MI (1975) A morphohistochemical study of the embryotropic action of steroids with androgenic properties. Arkh Patol 37:45–50
Rands PL, White RD, Carter MW, Allen SD, Bradshaw WS (1982) Indicators of developmental toxicity following prenatal administration of hormonally active compounds in the rat. I. Gestational length. Teratology 25:37–43
Eibs HG, Spielmann H, Hagele M (1982a) Teratogenic effects of progestin treatment during the pre- and postimplantation period of mouse embryos. Teratology 22:288–289
Eibs HG, Spielmann H, Jacob-Muller U, Klose J (1982b) Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. II. Cyproterone acetate and medroxyprogesterone acetate treatment before implantation in vivo and in vitro. Teratology 25:291–299
Kricker A, Elliott JW, Forrest JM, McCredie J (1986) Congenital limb reduction deformities and use of oral contraceptives. Am J Obstet Gynecol 155:1072–1078
Yovich JL, Turner SR, Draper R (1988) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 38:135–144
Yovich JL, Turner SR, Draper R (1989) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Obstet Gynecol Surv 44:447–449
Pardthaisong T, Yenchit C, Gray R (1992) The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45:313–324
Anon (1982) Pregnancy categories for prescription drugs. FDA Drug Bull 12:24–25
Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES et al (1995) Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 10:330–336
Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS (2002) Pregnancies diagnosed during Depo-Provera use. Contraception 66:169–172
Wooltorton E (2005) Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. J Ayub Med Coll Abbottabad 172:746
FDA (2005) Depo-Provera (medroxyprogesterone acetate injectable suspension) revised product monograph, Pfizer. Available: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Depo (click on: November 2004—Label—Pfizer) (Accessed 8 Feb 2005)
Sannes E, Lyngset A, Nafstad I (1983) Teratogenicity and embryotoxicity of orally administered lynestrenol in rabbits. Arch Toxicol 52:23–33
Barlow SM, Knight AF, Sullivan FM (1980) Diazepam-induced cleft palate in the mouse: the role of endogenous maternal corticosterone. Teratology 21:149–155
Prahalada S, Hendrickx AG (1983) Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (Macaca mulatta). Teratology 27:215–222
Tarara R (1984) The effect of medroxyprogesterone acetate (Depo-Provera) on prenatal development in the baboon (Papio anubis): a preliminary study. Teratology 30:181–185
Prahalada S, Carroad E, Cukierski M, Hendrickx AG (1985) Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis). Teratology 32:421–432
Poggel A, Hendrickx AG, Korte R, Leuschner F, Neumann BW, Prahalada S, Binkerd PE, Gunzel P (1987) Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate + ethinylestradiol and progesterone + estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocephalus). Teratology 35:119–127
Carbone JP, Figurska K, Buck S, Brent RL (1990) Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate. Teratology 42:121–130
Carbone JP, Brent RL (1993) Genital and non genital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am J Obstet Gynecol 169:1292–1298
Jordan A (1994) Toxicology of depot medroxyprogesterone acetate. Contraception 49:189–201
Bishun N, Mills J, Parke JV, Williams DC (1975) A cytogenetic study in women who had used oral contraceptives and in their progeny. Mutat Res 33:299–310
Klinger HP, Glasser M, Kava HW (1976) Contraceptives and the conceptus. I. Chromosome abnormalities of the fetus and neonate related to maternal contraceptive history. Obstet Gynecol 48:40–48
Muller R, Ritter C (1978) Cytogenetic studies on women during and following the use of hormonal contraceptives. Zentralbl Gynakol 51:125–129
Tu ZH, Wang MY, Qi XD, Xu WB, Xu DH (1992) Lack of mutagenicity and teratogenicity of 16-methylene–17-alpha-acetoxy-19-norprogesterone. Zhongguo Yao Li Xue Bao 13:183–186
Shyama SK, Abdul Rahiman M (1993) Progestin (norethisterone)-induced genetic damage in mouse bone marrow. Mutat Res 300:215–221
Herzog R, Leuschner J, Henning (1995) Evaluation of the mutagenicity of medroxyprogesterone acetate in vitro and in vivo. Arzneimittelforschung 45:311–314
Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA (2001) Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61:293–302
Giovanni B, Martelli A (2002) Are some progestins genotoxic liver carcinogens? Mutation Research 512:155–163
Kremer J, de Bruijn HW, Hindriks FR (1980) Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate. Contraception 22:359–367
Crona N, Enk L, Friberg LG, Samsioe G, Silfverstolpe G (1983) Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate. Gynecol Obstet Invest 18:16–20
Gronroos M, Lehtonen A (1983) Effect of high dose progestin on serum lipids. Atherosclerosis 47:101–105
Liew DF, Ng CS, Yong YM, Ratnam SS (1985) Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31:51–64
Enk L, Crona N, Friberg LG, Samsioe G, Silfverstolpe G (1985) High-dose depot-medroxyprogesterone acetate—effects on the fatty acid composition of serum lecithin and cholesterol ester. Gynecol Oncol 22:317–323
Fahraeus L, Sydsjo A, Wallentin L (1986) Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 45:503–506
Wallace EM, Wu FCW (1990) Effect of medroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man. Contraception 41:63–71
Garza-Flores J, De la Cruz DL, Valles de Bourges V, Sanchez-Nuncio R, Martinez M, Fuziwara JL, Perez-Palacios G (1991) Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44:61–71
Enk L, Landgren BM, Lindberg UB, Silfverstolpe G, Crona N (1992) A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 24:85–89
Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, Valles de Bourges V, Cruz DL, Perez-Palacios G, Rosseneu M (1993) A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. Contraception 47:177–191
Miller BG, Moore NW (1983) Endometrial protein secretion during early pregnancy in entire and ovariectomized ewes. J Reprod Fertil 68:137–144
Canto de Cetina TE, Luna MO, Cetina Canto JA, Bassol S (2004) Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception 69:115–119
Topcuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topcuoglu D (2005) The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 205:79–86
Bursch W, Taper HS, Lauer B, Schulte-Hermann R (1985) Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows Arch B Cell Pathol Incl Mol Pathol 50:153–166
Tucker MJ, Kalinowski AE, Orton TC (1996) Carcinogenicity of cyproterone acetate in the mouse. Carcinogenesis,l 17:1473–1476
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bakry, S., Merhi, Z.O., Scalise, T.J. et al. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet 278, 1–12 (2008). https://doi.org/10.1007/s00404-007-0497-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-007-0497-z